Service d'Hématologie Clinique, Centre Hospitalier Universitaire, Côte de Nacre, Caen Cedex, France.
Blood. 2011 Jan 27;117(4):1315-8. doi: 10.1182/blood-2010-07-295378. Epub 2010 Nov 15.
Acute myeloid leukemia (AML) patient outcomes remain heterogeneous, and new prognostic tools are needed to assess the risk of relapse. Hematogones (HGs) are normal B-lymphocyte precursors, which increase in number in hematologic diseases. The prognostic impact of the presence of detectable HGs on the leukemia-free survival (LFS) and overall survival of 120 consecutive patients with AML in first complete remission was investigated by flow cytometry. Patients who had HG levels more than 0.01% had a significantly better median LFS (29.2 vs 11.7 months; P = .001) and overall survival (not reached vs 23.5 months; P = .011). According to Cox analysis, an HG level more than 0.01% was an independent predictor of LFS (hazard ratio = 0.5; 95% confidence interval, 0.28-0.90, P < .03) when age, leukocytosis, the number of chemotherapy cycles, and the standardized cytogenetic and molecular risk subgroups were controlled for. These results indicate that HG analysis may help to define the risk of relapse in AML patients.
急性髓系白血病（AML）患者的预后仍然存在异质性，需要新的预后工具来评估复发的风险。造血细胞（HGs）是正常的 B 淋巴细胞前体，在血液疾病中数量增加。通过流式细胞术研究了 120 例在首次完全缓解的 AML 患者中可检测到的 HGs 对无白血病生存（LFS）和总生存的存在对预后的影响。HG 水平超过 0.01%的患者中位 LFS（29.2 与 11.7 个月；P =.001）和总生存（未达到与 23.5 个月；P =.011）明显更好。根据 Cox 分析，在控制年龄、白细胞增多、化疗周期数、标准化细胞遗传学和分子危险亚组后，HG 水平超过 0.01%是 LFS 的独立预测因子（危险比= 0.5；95%置信区间，0.28-0.90，P <.03）。这些结果表明，HG 分析可能有助于确定 AML 患者的复发风险。
